Crizotinabex (Crizomax)
Product detail for Crizotinabex, INN: crizotinabex. Therapeutic area: Oncology. This record shows all linked substances, markets, applications, presentations, and labeling artefacts.
Product ID
PROD-028
INN
crizotinabex
Therapeutic Area
Oncology
Status
Pending
Owner
Lieselotte van der Berg
Created
2022-03-11
Last Updated
2024-01-02
Markets
3
Presentations
| Form | Strength | Route |
|---|---|---|
| Oral solution | 100 mg/mL | Transdermal |
| Soft capsule | 200 mg | Intravenous |
| Ophthalmic solution | 5 mg/mL | Intravenous |
Active Substances
| ID | Name | INN | CAS | Type | Status |
|---|---|---|---|---|---|
| SUB-024 | Semaglutidex | semaglutidex | 51393-36-2 | small-molecule | Active |
| SUB-041 | Methionine | methionine | 90591-98-6 | small-molecule | Pending |
Applications (3)
| Application # | Market | Procedure Type | Status | Owner | Submitted |
|---|---|---|---|---|---|
| MHRA-2022-0028 | Austria | sMAA | Failed | Tomoko Ikeda | 2022-08-15 |
| SAHPRA-2022-0058 | Austria | sMAA | Failed | Priya Sharma | 2023-10-16 |
| MHRA-2022-0088 | Austria | sMAA | Completed | Nadia Petrova | 2023-03-26 |
Markets (3)